Humanalbumin, Hydroxyethylstarch and Ringer Lactate During Cardiac Surgery
NCT ID: NCT01174719
Last Updated: 2015-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
240 participants
INTERVENTIONAL
2006-03-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Main Outcome parameters: chest tube drainage and coagulation parameters. The investigators hypothesis is that HES is as safe as Albumin, however less expensive. Whether RL is an even less expensive and as safe alternative has to be shown.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Albumin in Cardiac Surgery
NCT02560519
Lactated Ringer's Versus 5% Human Albumin: Cardiac Surgical Patients
NCT02654782
Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement
NCT05391607
Impact of Hyperoncotic Albumin to Support Blood Loss Replacement
NCT03848507
Comparison of Priming Constituents in Patients Undergoing CPB Assisted Cardiac Surgery: HES 130/0.4 or Albumin 5%
NCT01849757
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hydroxyethylstarch
volume replacement
Hydroxyethylstarch up to 50mL/kg/24 hrs
Humanalbumin
Humanalbumin 5%
Humanalbumin 5% up to 50 mL/kg/24 hours
Ringer lactate
volume replacement
up 10 50mL/kg/24 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
volume replacement
Hydroxyethylstarch up to 50mL/kg/24 hrs
Humanalbumin 5%
Humanalbumin 5% up to 50 mL/kg/24 hours
volume replacement
up 10 50mL/kg/24 hours
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Coronary bypass surgery
Exclusion Criteria
* Coagulation disorders
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eva M. Base
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eva M Base, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University of Vienna
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vienna General Hospital
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HAHes
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.